Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Low-dose Pilocarpine Spray to Treat Xerostomia

Author(s):  Zur Eyal

Issue:  Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue

Page(s):  104-108

Low-dose Pilocarpine Spray to Treat Xerostomia Page 1
Low-dose Pilocarpine Spray to Treat Xerostomia Page 2
Low-dose Pilocarpine Spray to Treat Xerostomia Page 3
Low-dose Pilocarpine Spray to Treat Xerostomia Page 4
Low-dose Pilocarpine Spray to Treat Xerostomia Page 5

Download in electronic PDF format for $75

Abstract:  Although pilocarpine hydrochloride tablets are currently indicated for the treatment of xerostomia, their adverse effects are frequently reported. The development of a new, low-dose pilocarpine solution for topical oral-cavity use is needed. This article discusses a few clinical trials to formulate a topical low-dose solution of pilocarpine hydrochloride for the treatment of xerostomia and presents two low dose, stable formulations of pilocarpine topical spray that can improve the patient's quality of life with minimal adverse effects.

Related Keywords: xerostomia, dry mouth, Sjögren syndrome, head and neck radiotherapy, aging, pilocarpine hydrochloride, saliva secretion stimulant, cholinergic agonist, muscarinic activation, mucin, cevimeline, adverse effects, formulations, dosage forms, topical preparation, oral spray

Related Categories: DENTAL, EAR NOSE THROAT, FORMULATIONS, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Low-dose Pilocarpine Spray to Treat Xerostomia
Zur Eyal
Mar/Apr 2020
Pg. 104-108

Pilocarpine Hydrochloride 0.3% w/v Solution
Allen Loyd V Jr
Mar/Apr 2023
Pg. 149-151

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M
, Collin Michael
May/Jun 2016
Pg. 197-201

Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin
, Carvalho Maria, Banov Fabiana
Nov/Dec 2023
Pg. 468-473

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer
, Weinstock Leonard B, Thomas Erin
Mar/Apr 2010
Pg. 171-173

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George
, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jul/Aug 2018
Pg. 270-278

Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B
, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020
Pg. 94-96

Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum
Zur Eyal
Mar/Apr 2012
Pg. 117-124

Saliva Substitute for Dry Mouth/Throat
Allen Loyd V Jr
May/Jun 2000
Pg. 215

Clinical Management and Review of Sjogren's Syndrome
Dyke Shannon
Sep/Oct 2000
Pg. 338

Xerostomia
Kuntz Rachael
, Allen Michelle, Osburn Jennifer
May/Jun 2000
Pg. 176-177

Dry Mouth Spray
Horwitz Robert
Jul/Aug 2000
Pg. 255

Burning Mouth Syndrome: A Discussion of a Complex Pathology
Zur Eyal
May/Jun 2012
Pg. 196-205

Surviving Cancer - How the Compounding Pharmacist Can Help
Maddox Suzan
Jul/Aug 2000
Pg. 257-260

Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
Nov/Dec 2003
Pg. 460-463

View Sample
Pilocarpine HCl 2-mg Troches
Allen Loyd V Jr
Sep/Oct 2000
Pg. 381

Pilocarpine Oral Solution
Allen Loyd V Jr
May/Jun 2000
Pg. 177

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Sumatriptan 5-mg or 20-mg per 100-μL Nasal Spray
Allen Loyd V Jr
Mar/Apr 2016
Pg. 147

Equine Cushing’s Syndrome
Vail Jane
Jan/Feb 2003
Pg. 27-29

Return to Top